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Table 2.  Markers and dyes used in flow cytometry. Four panels (T cells, myeloid cells, intracellular 
cytokine for T cell subtype, nuclear factor in Tregs) are included.
Introduction
• Immune checkpoint inhibitor (ICI) therapy has revolutionized 
cancer therapy; however, ICIs cause life/organ-threatening 
inflammatory phenomenon, termed immune-related adverse events 
(irAEs). Inflammatory arthritis is the most common rheumatic irAEs, 
occurring 3-5% of patients receiving ICI therapy. 
• CTLA-4 monotherapy barely induces arthritis-irAE, while PD-1 
monotherapy and combination therapy does.
• Mechanism of irAEs are unknown, mainly due to lack of pre-clinical 
mouse models.
• Hence, we would like to generate pre-clinical model recapitulating 
patients with arthritis induced by immune checkpoint inhibitors 
(arthritis-irAE) 
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Methods
T Cells Myeloid ICS NF
BV421 SiglecF IL-17 IL-10
AmCyan Dead Dead Dead Dead
BV786 Ly6G IFNg IFNg
PerCP CD8 MHCII GM-CSF CTLA-4
FITC-A CXCR3 CD19 CD8 FoxP3
PE-A CXCR5 CD3 CX3CR1 CD3
Alexa Fluor 700-A CD4 F4/80 CD4
PE-Cy7-A CD11B TNFa
PE-CF594A CD8
APC-A CCR6 Ly6C IL-4 IL-17
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Fig 1. (A) Weight Change over time (B) Representative pictures of CII-CFA+CII-IFA mice receiving PBS (no ICI) 



















































CXCR5- CD8 T Cells
A
Table 1. We immunized chicken collagen (CII) emulsified with complete Freud media (CFA) in 8-10 weeks male 
C57/B6 mice on Day 0. Mice were re-challenged on Day 21 with incomplete Freud media (IFA). PBS, anti-CTLA-4, 
and/or anti-PD-1 antibodies were injected on Day 19, 22, 25, and 28. CIA mice (CII-CFA on Day 0 and Day 21) 
receiving combined ICIs were used as positive controls. The incidence and severity of arthritis were measured until 
they were sacrificed on Day 43. At sacrifice, we harvested spleen, bones, and serum. 
• ICI induced arthritis in mice receiving CII/CFA and IFA
• CTLA4 monotherapy induced arthritis at later time and was 




Fig 2. Delineation of major immune cell subsets of spleen. (A) Flow cytometry to show the gating strategy. (B) 
Quantitative analysis. 
B
A: No ICIs    B: + aCTLA-4    C: +aPD-1    D: aCTLA-4+aPD-1    E: CII-CFA+CII-CFA






















































Fig 5. Comparison of Treg subpopulation. (A) Flow cytometry to show the gating strategy and quantitative analysis of all 
Tregs. (B) Quantitative analysis on anti-inflammatory Tregs . 





1. Since CTLA-4 monotherapy group developed arthritis rapidly 
on D32 after weight loss, we should sacrifice mice before D32





D19 D22 D28 D43 
ICIs
Group D0 D21 ICIs Significance
A CII/CFA IFA None Neg Cont
B CII/CFA IFA aCTLA-4 Group of interest
C CII/CFA IFA aPD-1 Group of interest
D CII/CFA IFA aCTLA-4 + aPD-1 Group of interest




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A: No ICIs    B: + aCTLA-4    C: +aPD-1    D: aCTLA-4+aPD-1    E: CII-CFA+CII-CFA
























































































































































































































































































































































































































































































































































































































































































































A: No ICIs    B: + aCTL -4    C: +aPD-1    D: aCTLA 4+aPD-1    E: CII-CF +CII-CFA
Fig 4. Comparison of intracellular cytokine expression levels. (A) Fl w cytometry to show the gating strategy. (B) 
Quantitative analysis. 
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